SOURCE: SciClone Pharmaceuticals, Inc.

March 05, 2008 06:30 ET

SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results on March 13, 2008

FOSTER CITY, CA--(Marketwire - March 5, 2008) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report fourth quarter and year-end results for 2007 on Thursday, March 13, 2008, and it will host a conference call at 11:00 a.m. ET that day.

Management will review its operating results for the fourth quarter and fiscal year 2007, give a business and product update and provide guidance for 2008. A live webcast can be accessed by visiting the Investor Relations section of the Company's website at

DATE:          Thursday, March 13, 2008
TIME:          11:00 a.m. ET (8:00 a.m. PT)
WEBCAST:       Live call and replay accessible at
LIVE CALL:     (877) 419-6598 (U.S./Canada)
               (719) 325-4847 (International)
REPLAY:        (888) 203-1112 (U.S./Canada)
               (719) 457-0820 (International)
               Passcode:  8432220
               (Replay available from 2:00 p.m. ET on March 13, 2008
               through 11:59 p.m. ET on April 13, 2008)

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in late-stage clinical trials for the treatment of hepatitis C and malignant melanoma. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage and broaden its portfolio in the rapidly growing Chinese market by in-licensing or acquiring the marketing rights to other products, such as DC Bead™. For the U.S. market, SciClone's other clinical-stage drug development candidates are RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of hepatitis C. For more information about SciClone, visit

Contact Information

  • Corporate Contact:
    Richard Waldron
    Executive Vice President & Chief Financial Officer
    SciClone Pharmaceuticals, Inc.
    (650) 358-3437